pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Cure for HIV must protect long-term survivors from loss of benefits

Aug 21, 2026·read at STAT ↗Neutral

The authors, a postdoctoral researcher, a long‑term HIV survivor, and the head of a survivor alliance, argue that a future HIV cure should not jeopardize the support systems that have kept many patients alive.

They warn that without clear policy safeguards, a cure-or even durable viral control-could be interpreted as a reason to end benefits and services for long‑term survivors, creating a “benefits cliff.”

The piece calls on policymakers to anticipate these issues now, ensuring that medical breakthroughs are paired with protections for those who have depended on existing assistance.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: A cure for HIV would be a triumph. But it shouldn’t harm survivors”

read at STAT ↗
1,342 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
University of Pennsylvania2Ultragenyx Pharmaceutical Inc.
topics
Nephrology2CardiologyDuchenne Muscular DystrophyOncologyRare Disease

related stories

  • Jul 30New funding, new jobs: 4 biotechs hiring after series B raisesBioSpace
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Abcuro secures $66M; InduPro assembles $77MFierce Biotech
  • 1d agoSTAT+: Capricor Therapeutics’ Duchenne treatment is heading for an FDA rejectionSTAT
  • 1d agoReduce protein to increase longevity? Nutrition experts say that’s a bad ideaSTAT